Why Truly Personalized Medicine Is Oncology's Next Big Frontier

This is part 4 of an interview. Watch part 1, part 2, and part 3.

In the final segment of the interview, Joyce Ohm, PhD, looks ahead to what she sees as the next major frontier in oncology: truly personalized medicine. She emphasizes that every patient's tumor is biologically unique, and the ultimate goal of the field is to identify the single best treatment for each individual patient's specific disease, rather than relying on one-size-fits-all approaches.

Ohm notes that meaningful progress is already underway. The identification of "actionable mutations"—genetic changes with known clinical significance—now allows physicians to make more informed treatment decisions, choosing between therapies based on the molecular characteristics of a patient's tumor rather than general disease categories alone. This represents a significant step beyond traditional, broadly applied cancer treatments.

However, she is candid that the field still has considerable ground to cover. Fully understanding the specific molecular drivers behind any given patient's tumor remains an ongoing challenge, and developing truly targeted therapies that precisely hit those individual drivers is the next major hurdle. In her view, this—the pursuit of a genuinely individualized, mechanism-specific approach to cancer treatment—is the defining challenge facing the field going forward.

Ohm also points out that scale is a critical factor in this effort. Analyzing tumors at the molecular level for every patient, and translating that data into actionable treatment decisions, requires significant technological infrastructure and processing capability. Encouragingly, she notes that the pace of technological advancement continues to accelerate rapidly, suggesting that the field is moving toward this goal of comprehensive personalized medicine faster than might have been expected even a few years ago.

Overall, this closing reflection ties together the earlier discussion: genome sequencing provided the foundational tools, ethical frameworks are evolving to manage its responsible use, and the future lies in refining these capabilities into fully personalized, targeted cancer treatments for every patient.

Read the full interview with Dr Ohm.